



Board of Pharmacy

Ohio Board of Pharmacy Releases Guidance on the Compounding of GLP-1 Drug Products

The Ohio Board of Pharmacy (Board) has received inquiries concerning the compounding of GLP-1 (Glucagon-like Peptide-1) medications such as semaglutide and tirzepatide. Semaglutide is available as a commercially available drug product marketed as Ozempic™ and Rybelsus™ for treating diabetes and as Wegovy™ for weight loss. Tirzepatide is available as a commercially available drug product marketed as Mounjaro™ for treating diabetes and as Zepbound™ for weight loss.

To assist licensees in complying with state and federal law on drug compounding, the Board developed the following frequently asked questions document: www.pharmacy.ohio.gov/GLP1

For questions, please review the [FAQ](#). If you need additional information, the most expedient way to have your questions answered will be to e-mail the Board office by visiting: <http://www.pharmacy.ohio.gov/contact.aspx>.



People call, text, and chat the 988 Lifeline to talk about a lot of emotional needs—not just thoughts of suicide. Whatever your reason, the #988Lifeline is there to help. There is hope.



Ohio Board of Pharmacy
Mike DeWine, Governor | Steven W. Schierholt, Executive Director

Ohio Board of Pharmacy | 77 S. High St 17th Floor | Columbus, OH 43215 US

[Unsubscribe](#) | [Constant Contact Data Notice](#)